Eli Lilly reports second-quarter results on August 5, with the Street looking for roughly $20.26 billion in sales and $6.71 in earnings per share. The context around that print is more interesting than the print itself: the FDA has approved Foundayo, Lilly's once-daily orforglipron pill, for adults with obesity and for overweight adults with weight-related conditions.
An oral GLP-1 is the thing this entire category has been waiting for.
The setup
| Metric | Reading |
|---|---|
| Q2 2026 sales, consensus | ~$20.26B |
| Q2 2026 EPS, consensus | $6.71 |
| FY2026 revenue guidance | $82–85B (raised from $80–83B) |
| FY2026 adjusted EPS guidance | $35.50–37.00 |
| Foundayo (orforglipron) | FDA approved, once-daily oral |
| Phase 3 read-outs | Switch from injectable to oral: positive |
| Phase 3, T2D + obesity at CV risk | Positive |
Why a pill changes the math
Injectable GLP-1s work. Their constraint has never been efficacy — it has been manufacturing and adherence. Sterile injectable capacity is expensive, slow to build, and has been the binding limit on how fast this market could grow. Patients also drop off injectables at rates that would be unacceptable in most chronic categories.
A small molecule taken once a day removes both constraints at once. Oral manufacturing scales at a fraction of the cost and time. Adherence in a pill format is a different behavioral problem entirely. And the addressable population expands beyond the patients willing to inject themselves weekly — which, whatever the clinical data says, is a real filter on the market.
The Phase 3 data showing patients successfully switching from injectable incretins to oral therapy is the specific detail I'd focus on. That is not just a new-patient story; it is a migration path for an installed base, and it protects the franchise rather than fragmenting it.
The part I'd be careful about
Approval is not a launch. The distance between an FDA decision and a revenue line is measured in payer coverage, formulary placement, and pricing — and in this category, pricing is politically live in a way it is not for most drugs.
The competitive picture also matters and it is not a monopoly. Novo Nordisk is not standing still, and an oral format lowers the barrier for everyone eventually. First mover in a pill is worth a great deal, but the moat is manufacturing scale and payer relationships, not the molecule.
There is a valuation point too. Lilly has been priced for GLP-1 dominance for some time. The guidance raise to $82–85 billion is real and already known. For the stock to work from here, the launch has to beat a bar the market has already set, and launch quarters are notoriously messy — inventory stocking, uneven coverage, and gross-to-net dynamics all distort the first few prints.
My take
I treat tomorrow's report as the least important part of this story. The quarter will be fine or slightly better than fine; the guidance is already raised; and none of it tells you what the oral franchise is worth.
What I want from the call is granularity on the launch: script trends since approval, payer coverage as a percentage of covered lives, and manufacturing capacity for the oral formulation specifically. If management gives capacity numbers, that is the number to model from — in this category, supply has been the ceiling on demand for three straight years.
The long-term case here doesn't rest on beating a quarterly consensus. It rests on whether obesity treatment becomes a chronic, primary-care, pill-based category the way statins did. If it does, the addressable market is not what current forecasts assume. If it stays a specialist injectable category with an oral option, the stock is roughly fairly priced.
Bottom line: the approval is the event, not the earnings. Watch payer coverage and oral manufacturing capacity — those decide whether the pill is a product or a platform.
This is analysis, not investment advice.